The effects of doxazosin on plasma lipid and lipoprotein levels in hypertensive patients.
Plasma lipid and lipoprotein levels were evaluated in 27 adults with essential hypertension at four different periods during a 12-month treatment with doxazosin. Mean plasma total cholesterol (TC), low-density lipoprotein-cholesterol (LDLC), triglyceride (TG), very low density lipoprotein-cholesterol (VLDLC) and the LDLC/HDLC ratio were significantly reduced following doxazosin therapy. The HDLC/C ratio was found to be increased, while mean high density lipoprotein cholesterol (HDLC) level remained unchanged at 3, 6, 9 and 12 months of measurement after doxazosin treatment. Our data showed that the duration of doxazosin treatment did not influence the observed favourable lipid changes; but TC and LDLC appear to be the lipid fractions most affected by doxazosin in all the patients. In order to determine the possible factors responsible for the lipid-altering actions of doxazosin treatment, we observed beneficial lipid and lipoprotein changes in both the male and female subpopulations of patients with a slightly higher magnitude in the females. The dosage of doxazosin was, however, found to have no influence on the lipid-altering actions; a further study was therefore recommended.